Patents Represented by Attorney Lewis J. Kreisler
-
Patent number: 8338480Abstract: Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a combination of a direct PPAR-gamma agonist and a Compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) Three of R1, R2, R3, R4 and R5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; and m is 0, 2 or 4. R6 is hydrogen, O or hydroxy, and X is —OR7, wherein R7 is hydrogen or alkyl having from 1 to 3 carbon atoms; or R6 is hydrogen, and X is —NR8R9, wherein R8 is hydrogen or hydroxy and R9 is hydrogen, methyl or ethyl. When X is —NR8R9, hydroxy none of R1, R2, R3, R4 and R5 is hydroxy.Type: GrantFiled: March 5, 2007Date of Patent: December 25, 2012Assignee: Wellstat Therapeutics CorporationInventors: Reid W. von Borstel, Kirvin L. Hodge
-
Patent number: 8338384Abstract: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.Type: GrantFiled: May 23, 2010Date of Patent: December 25, 2012Assignee: Novartis AGInventors: Romulus Kimbro Brazzell, Peter Anthony Campochiaro, Katharine Hilary Dixon, Michael Kaleko, Tianci Luo
-
Patent number: 8287836Abstract: Methods of preparing single walled carbon nanotubes are provided. Carbon containing gas is contacted with a supported metal catalyst under reaction conditions to yield at least 90% single walled carbon nanotubes and at least 1 gram single walled carbon nanotubes/gram metal catalyst. The support material may be calcined at temperatures between 150 and 600° C., and may have at least one oxidized planar surface. Reaction conditions include less than 10 atmospheres pressure and less than 800° C.Type: GrantFiled: August 20, 2007Date of Patent: October 16, 2012Assignee: Hyperion Catalysis International, Inc.Inventors: Xinjie Zhang, Jun Ma, Howard Tennent, Robert Hoch
-
Patent number: 8234129Abstract: A system and method for assessing immunological status of individuals and populations is presented. The method includes establishing a database containing a plurality of records, each record containing information representative of the immune status of an individual, including (1) bioassay results, and (2) individual specific information such as, medical history, clinical observations and historical, demographic, lifestyle, and familial/genetic information. By processing the information trends and/or patterns are obtained correlating various variables in the records across an individual, population or sub-population. The identified trends and/or patterns can, for example, be used in health care related decision making. In exemplary embodiments such processing can include generating a set of correlations and for each correlation generating a set of explanatory or relevant hypotheses. Then, for example, each hypothesis can be automatically refuted or supported, to the extent possible.Type: GrantFiled: April 27, 2007Date of Patent: July 31, 2012Assignee: Wellstat Vaccines, LLCInventors: Francis Michon, Samuel L. Moore, Peter C. Fusco, Samuel J. Wohlstadter, Charles Quentin Davis, Aaron Haleva
-
Patent number: 8178675Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed as Formula (I).Type: GrantFiled: November 9, 2006Date of Patent: May 15, 2012Assignee: Wellstat Therapeutics CorporationInventors: Fedor Evgenievich Romantsev, Shalini Sharma, Reid W. von Borstel, Stephen D. Wolpe
-
Patent number: 8044243Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is unsubstituted or substituted phenyl; or cycloalkyl; or a 5 or 6 membered heteroaromatic ring. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula I.Type: GrantFiled: February 9, 2007Date of Patent: October 25, 2011Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Patent number: 8022249Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.Type: GrantFiled: March 31, 2006Date of Patent: September 20, 2011Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Patent number: 8012480Abstract: The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib.Type: GrantFiled: April 18, 2007Date of Patent: September 6, 2011Assignee: Wellstat Biologics CorporationInventor: Robert M. Lorence
-
Patent number: 7973052Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.Type: GrantFiled: February 25, 2009Date of Patent: July 5, 2011Assignee: Wellstat Therapeutics CorporationInventors: Kirvin L. Hodge, Shalini Sharma, Reid W. von Borstel, Stephen D. Wolpe
-
Patent number: 7947735Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R1 is hydrogen, halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; one of R4 and R5 is hydrogen or hydroxy and the other is hydrogen; or R4 and R5 together are ?O; R6 is hydrogen or alkyl having one, two, three, four or five carbon atoms; or a pharmaceutically acceptable salt of the compound. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).Type: GrantFiled: January 22, 2007Date of Patent: May 24, 2011Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Patent number: 7935689Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R3 and R4 together are alkyl having two or three carbon atoms; or R3 and R4 are the same as each other and each is methyl or ethyl; R5 is hydrogen or alkyl having from one to six carbon atoms.Type: GrantFiled: May 11, 2007Date of Patent: May 3, 2011Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Patent number: 7932290Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.Type: GrantFiled: August 31, 2009Date of Patent: April 26, 2011Assignee: Wellstat Biologics CorporationInventors: Kirvin L. Hodge, Shalini Sharma, Albert C. Lee, Reid W. von Borstel
-
Patent number: 7914979Abstract: Envelope viruses (e.g. Newcastle disease virus (NDV)) are formulated for storage at moderately cold temperatures (e.g. ?20° C.). The formulation is an aqueous solution containing the enveloped virus at a concentration of from 106 PFU/mL to 1012 PFU/mL; and a non-reducing saccharide (e.g. sucrose). When the non-reducing saccharide is a disaccharide it is present in the solution at a concentration of from 5% (w/v) to 50% (w/v), and when it is a monosaccharide it is present in the solution at a concentration of from 2.5% (w/v) to 25% (w/v). The solution has an osmotic pressure of about 250 mOs or higher, and has a pH of from 5 to 10.Type: GrantFiled: November 4, 2005Date of Patent: March 29, 2011Assignee: Wellstat Biologics CorporationInventors: Tzer-Fen Chen, Jouhn-Wern Jang, Jeffrey A. Miller
-
Patent number: 7915429Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula (Type: GrantFiled: January 22, 2007Date of Patent: March 29, 2011Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Patent number: 7906675Abstract: A biologically active agent, wherein the agent is a compound of the formula: Wherein A, R5, R9, X, Q and n, m, q are defined herein below.Type: GrantFiled: August 16, 2004Date of Patent: March 15, 2011Assignee: Wellstat Therapeutics CorporationInventor: Shalini Sharma
-
Patent number: 7863475Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: August 24, 2007Date of Patent: January 4, 2011Assignee: Wellstat Therapeutics CorporationInventor: Shalini Sharma
-
Patent number: 7851494Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: July 2, 2007Date of Patent: December 14, 2010Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel, Kirvin L. Hodge, Michael K. Bamat, Stephen D. Wolpe
-
Patent number: 7820721Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.Type: GrantFiled: January 22, 2007Date of Patent: October 26, 2010Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Patent number: 7776838Abstract: The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.Type: GrantFiled: June 2, 1995Date of Patent: August 17, 2010Assignee: Wellstat Therapeutics CorporationInventors: Reid W. von Borstel, Michael K. Bamat
-
Patent number: 7749990Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.Type: GrantFiled: September 11, 2008Date of Patent: July 6, 2010Assignee: Wellstat Therapeutics CorporationInventors: Kirvin L. Hodge, Shalini Sharma, Reid W. von Borstel